Market Access News | pharmaphorum

News

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

News

The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.

News

In a blow to UK life science ambitions, MSD has scrapped a £1bn expansion of its operations in the country, saying it does not value innovation.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

League tables for NHS trusts will end the postcode lottery of care, says the government, but not all are convinced.

News

The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.